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Abstract Human homologue of Drosophila ariadne (HHARI)
is a RING-IBR-RING domain protein identi¢ed through its
ability to bind the human ubiquitin-conjugating enzyme,
UbcH7. We now demonstrate that HHARI also interacts with
the eukaryotic mRNA cap binding protein, translation initiation
factor 4E homologous protein (4EHP), via the N-terminal
RING1 ¢nger of HHARI. HHARI, 4EHP and UbcH7 do
not form a stable heterotrimeric complex as 4EHP cannot im-
munoprecipitate UbcH7 even in the presence of HHARI. Over-
expression of 4EHP and HHARI in mammalian cells leads to
polyubiquitylation of 4EHP. By contrast, HHARI does not
promote its own autoubiquitylation. Thus, by promoting the
ubiquitin-mediated degradation of 4EHP, HHARI may have a
role in both protein degradation and protein translation.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The human homologue of ariadne protein (HHARI) was
isolated from a yeast 2-hybrid screen in which the ubiquitin-
conjugating enzyme (E2), UbcH7, was used as bait [1]. The
function of HHARI is unknown. However, its importance in
neurodevelopment was inferred from studies on the gene en-
coding its Drosophila orthologue, ariadne-1, which interacted
with UbcD10, the Drosophila orthologue of UbcH7 [2].
Although null mutations in Drosophila ariadne-1 yielded few
adult survivors, they manifested a short life-span, motor be-
havioural de¢cits and abnormal connectivity in the central
nervous system [2].
HHARI is characterised by the presence of a RING (really
interesting gene)-(in between RING) IBR-RING ¢nger signa-
ture that is found in a number of ubiquitin-protein ligases
(E3s) including Parkin and Dor¢n [1,3^7]. Indeed, the
RING ¢nger domain structure characterises the main class
of E3s [8^10]. Although many E3s are de¢ned by the presence
of this domain structure, not all RING ¢nger proteins are
necessarily E3s.
HHARI, Parkin and Dor¢n interact with the E2s, UbcH7
and/or UbcH8, through their RING-IBR-RING structures
[6,7,11]. Consequently, we proposed that HHARI is either a
protein that facilitates protein substrate ubiquitylation as a
component of an E3, or it is a substrate for protein ubiqui-
tylation. The aim of this study was to identify novel HHARI-
interacting proteins in order to understand the function of
HHARI in normal cells and provide clues to the neurological
phenotype observed when expression is lost.
2. Materials and methods
2.1. Materials
Mouse monoclonal anti-Myc (clone 9E10), and anti-FLAG M2
antibodies were obtained from Sigma. Mouse monoclonal anti-Myc
antibody clone 9B11 was obtained from Cell Signaling. Rabbit poly-
clonal anti-ubiquitin, and horseradish peroxidase-conjugated second-
ary antibodies were obtained from Dako. A⁄nity puri¢ed anti-
UbcH7 C-terminal peptide rabbit antisera was described previously
[1,4]. All reagents for Cytotrap yeast 2-hybrid screening were pur-
chased from Stratagene.
2.2. Cytotrap yeast 2-hybrid screen for HHARI-interacting proteins
The Cytotrap yeast 2-hybrid system was performed according to the
manufacturer’s instructions (Stratagene) in order to identify HHARI-
interacting proteins. This system is based upon the detection of inter-
acting proteins in the cytoplasm of yeast cells [12]. In brief, the open
reading frame of HHARI was used as ‘bait’ as a pSos.HHARI fusion
construct. pSos.HHARI (60 Wg) was used to screen a human testis
cDNA library in pMyr (60 Wg) as per the manufacturer’s protocol
(Stratagene).
Putative interactants were puri¢ed prior to transformation into the
Escherichia coli K12 strain, HB101. Plasmids were puri¢ed and the
sizes of cDNA inserts were determined by polymerase chain reaction
(PCR) using vector-speci¢c oligonucleotide primers. PCR amplicons
were sequenced.
2.3. Plasmid constructs
A series of HHARI-Myc deletion constructs in pcDNA3.1(-)/Myc-
His (Invitrogen) were generated by PCR using Pfu Turbo DNA poly-
merase (Stratagene) and HHARI-Myc as the template [4]. Similarly,
the full coding sequence of 4EHP was ampli¢ed from the yeast 2-hy-
brid 4EHP cDNA clone. BamHI and XhoI sites were incorporated
into the forward and reverse oligonucleotide PCR primers, respec-
tively. Amplicons were digested with BamHI and XhoI, gel puri¢ed
and cloned into FLAG-pcDNA3 or Myc-pcDNA3 vectors [13].
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2.4. Mammalian cell transfection, immunoprecipitation (IP) and
Western blot analysis
Procedures for transfection of human embryonic kidney (HEK)
293t cells using LipofectAMINE 2000 (Invitrogen), IP and sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE),
protein transfer and immunodetection were performed as described
in [4,13]. Working dilutions of primary antibodies were diluted in
1% (w/v) non-fat milk in phosphate-bu¡ered saline (PBS) as follows:
1:1000, mouse anti-FLAG antibodies; 1:100 and 1:1000, mouse 9E10
and 9B11 anti-Myc antibodies, respectively; 1:5000, a⁄nity puri¢ed
rabbit anti-UbcH7 peptide antibodies; 1:1000, rabbit anti-ubiquitin
antibodies. HRP-conjugated secondary antibodies were used at
1:3000 in 0.1% (w/v) non-fat milk in PBS.
3. Results
3.1. Isolation of HHARI-interacting proteins using the
Cytotrap yeast 2-hybrid system
cdc25H yeast cells were co-transformed with pSos.HHARI
and pMyr human testis cDNA library plasmids in order to
identify HHARI-interacting clones. Ninety yeast colonies
were initially identi¢ed, however only four of these proved
to be true interactants. The identities of the four clones
were determined by DNA sequence analysis to be UbcH7,
4EHP (twice ^ accession number AF047695) and an EST
of unknown function (accession number BM471831)
(Clone 4). 4EHP is 30% identical (and 60% similar) to the
human translation initiation factor, eIF4E, at the amino
acid level [14].
Co-transformation of plasmids containing pMyr.4EHP,
pMyr.UbcH7 and pMyr.Clone 4 with di¡erent control plas-
mids con¢rmed the speci¢city of interaction with pSOS.H-
HARI. Interestingly, strong interactions were observed be-
tween pSos.HHARI and pMyr.4EHP or pMyr.UbcH7, by
contrast, pSos.HHARI appeared to interact only weakly
with Clone 4.
3.2. HHARI interacts with 4EHP in mammalian cells
Co-IP of HHARI-Myc and FLAG-4EHP from transfected
HEK293t cells was performed in order to con¢rm the inter-
action between HHARI and 4EHP (Fig. 1A). HHARI-Myc
and FLAG-4EHP were expressed at approximately the same
levels in both singly and co-transfected cells (Fig. 1A, com-
pare lanes 6, 7 and 8). Equal loading of protein lysates was
Fig. 1. Interaction of 4EHP, UbcH7 and HHARI in HEK293t cells. A: HEK293t cells were transfected with the plasmid constructs indicated
and IPs performed as described in [4]. Immunoprecipitates were then analysed by SDS^PAGE (T=15%; C=2.5%) and Western blotting.
Twenty Wl of each total cell lysate was also analysed in parallel (No IP). The membrane was probed sequentially (after stripping) with mouse
anti-FLAG (K-FLAG) or anti-Myc antibodies (9B11) (K-Myc), a⁄nity puri¢ed rabbit anti-UbcH7 peptide antibodies (K-UbcH7) or anti-eIF4E
(K-eIF4E) antibodies. The positions of individual molecular mass markers are indicated. A: HHARI interacts with 4EHP in HEK293t cells.
B: Binding of 4EHP to HHARI is independent of binding of UbcH7. C: eIF4E does not interact with HHARI. HEK293t cells were trans-
fected with HHARI-Myc.
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con¢rmed from the approximate equal amounts of UbcH7
(Fig. 1A, bottom right panel).
IP with anti-Myc antibodies from lysates prepared from
cells transfected with either HHARI-Myc or FLAG-4EHP
alone led to the precipitation of HHARI-Myc (Fig. 1A, mid-
dle left panel, lane 2) but not FLAG-4EHP (Fig. 1A, upper
left panel, lane 1). Moreover, there was no evidence of other
cross-reacting cellular proteins (Fig. 1A, lanes 4 and 5). By
contrast, IP of HHARI-Myc with anti-Myc antibodies led
speci¢cally to the co-precipitation of FLAG-4EHP in cells
expressing both HHARI-Myc and FLAG-4EHP (Fig. 1A,
compare lane 3 with lanes 1, 2, 4 and 5). Endogenous
UbcH7 was also precipitated (Fig. 1A, lower left hand panel,
lane 3). Conversely, IP of FLAG-4EHP with anti-FLAG anti-
bodies (Fig. 1B, upper panel, lanes 1 and 3) did not result in
the co-precipitation of endogenous UbcH7 (Fig. 1B, lower
panel) although HHARI-Myc was co-precipitated (Fig. 1B,
middle panel, lane 3). These data inferred that binding of
UbcH7 and 4EHP to HHARI are mutually exclusive.
IP of HHARI-Myc from transfected HEK293t cells did not
co-immunoprecipitate endogenous eIF4E (Fig. 1C).
3.3. The RING1 domain of HHARI regulates its interaction
with 4EHP
Myc-tagged HHARI deletion constructs (Fig. 2A) were co-
transfected into HEK293t cells with FLAG-4EHP. All Myc-
tagged HHARI deletion proteins were expressed albeit at
slightly variable levels (Fig. 2B, lower panel). Similarly, a
consistent level of expression of FLAG-tagged 4EHP was ob- served in those cells transfected with the FLAG-4EHP con-
struct (Fig. 2B, right upper panel). Equal loading of protein
was con¢rmed by the consistent levels of UbcH7 expression
observed in the total cell lysates applied to each lane (Fig. 2B,
right middle panel).
Full-length HHARI-Myc, HHARI(1-237)-Myc, HHARI(1-
325)-Myc and HHARI(1-414)-Myc constructs immunopreci-
pitated FLAG-4EHP (Fig. 2B, upper left panel). By contrast,
HHARI(1-92)-Myc and HHARI(1-162)-Myc did not (Fig. 2B,
upper left panel). Although deletion mutant HHARI(1-237)-
Myc bound 4EHP, it did not bind UbcH7 (Fig. 2B, compare
middle and upper left hand panels, lane 6). These data imply
that the RING1 ¢nger domain is a key regulator of the inter-
action with 4EHP. However, it is not su⁄cient for binding
UbcH7 con¢rming results of our earlier studies [1,4]. Trans-
fection of deletion mutants lacking the Glycine rich region
and acidic domain of HHARI [4] con¢rmed that these do-
mains did not a¡ect binding to 4EHP (data not shown).
3.4. Overexpression of HHARI and 4EHP in HEK293t cells
leads to the polyubiquitylation of 4EHP
Observations that HHARI interacts speci¢cally with
UbcH7 [1,4], implied that HHARI might possess E3 activity
either towards itself or interacting proteins such as 4EHP.
Therefore, we analysed immunoprecipitates of HHARI-Myc
and FLAG-4EHP from cell lysates of HEK293t cells, cultured
in the presence and absence of the proteasome inhibitor
MG132, by Western blotting with anti-ubiquitin antibodies
(Fig. 3, upper panel). There was no evidence of HHARI au-
toubiquitylation either in the presence or absence of MG132
(Fig. 3, left upper panel) despite ample evidence of polyubiq-
uitylated products in the total cell lysates (Fig. 3, right upper
panel). By contrast, ubiquitylated FLAG-4EHP products
were observed when FLAG-4EHP was co-expressed with
Fig. 2. The RING1 domain of HHARI promotes interaction with
4EHP. A: Schematic of the domain structure of the HHARI-Myc,
and deletion constructs generated to establish the region of HHARI
that regulates interaction with 4-EHP. B: IP of FLAG-4EHP with
HHARI-Myc constructs described in A were undertaken as de-
scribed in Section 2 (IP with K-Myc ^ lanes 1^8). Twenty Wl of each
total cell lysate was also analysed in parallel (No IP ^ lanes 9^16).
The membrane was probed sequentially (after stripping) with mouse
anti-FLAG antibodies (K-FLAG), a⁄nity puri¢ed rabbit anti-
UbcH7 peptide antibodies (K-UbcH7) and mouse anti-Myc antibod-
ies (9B11) (K-Myc). The positions of individual molecular mass
markers are indicated.
Fig. 3. HHARI promotes polyubiquitylation of 4EHP in HEK293t
cells. HEK293t cells were transfected with HHARI-Myc and/or
4EHP constructs and cultured in the presence (+) or absence (^) of
5 WM MG132 for 16 h. After 48 h, Myc-tagged proteins were im-
munoprecipitated from 730 Wl transfected cell lysates with either
anti-Myc (K-Myc) or anti-FLAG (K-FLAG) antibodies. Immunopre-
cipitates were then analysed by SDS^PAGE and Western blotting.
Twenty Wl of each total cell lysate was also analysed in parallel (No
IP). The success of the IP was ascertained by Western blotting with
K-Myc (9B11) or K-FLAG antibodies as appropriate (lower panels).
The membranes were also probed with anti-ubiquitin antibodies
(K-Ub). The positions of individual molecular mass markers are in-
dicated. The vertical black bar at the right hand side of the blots in-
dicates high molecular mass proteins; * ^ monoubiquitin.
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HHARI-Myc that were not present in the absence of
HHARI-Myc (Fig. 3, upper middle panel, compare lane 9
with lanes 7 and 8). The levels of ubiquitylated FLAG-
4EHP increased when transfected cells were cultured in the
presence of MG132 both in the presence and absence of
HHARI-Myc (Fig. 3, middle panel, lanes 10 and 12).
4. Discussion
We have demonstrated that HHARI interacts speci¢cally
with 4EHP and UbcH7 using both Cytotrap yeast 2-hybrid
analysis and by co-IP from mammalian cells. The observation
that the Cytotrap system detected the interaction between
HHARI and UbcH7 con¢rmed earlier studies [1]. We note
that the Cytotrap system avoids problems of transactivation
that often occurs when using the classical yeast 2-hybrid sys-
tem with proteins containing RING ¢nger domain structures
[12]. IP of HHARI in the presence of 4EHP resulted in the co-
IP of UbcH7. However, 4EHP was not capable of co-immu-
noprecipitating UbcH7 independently of HHARI, suggesting
that a stable heterotrimeric complex does not exist between
these three proteins. Although the RING1 domain regulates
the interaction between HHARI and 4EHP, we have previ-
ously demonstrated that UbcH7 needs an additional 20 amino
acid residue sequence C-terminal to RING1 [1,4].
4EHP is homologous to eIF4E [14]. eIF4E is a component
of the eIF4F-mRNA cap binding complex that is essential for
cap-dependent protein synthesis [15]. eIF4F comprises eIF4A,
eIF4E and eIF4G and is responsible for the recruitment of
ribosomes to mRNA. [15]. During translation initiation,
eIF4F interacts with both the cap of mRNA (through
eIF4E) and the ribosome-associated eIF3 (through eIF4G).
eIF4F acts as a bridging factor between mRNA and ribo-
somes. eIF4E is found both in the cytoplasm and the nucleus
of cells [16,17]. Whereas cytoplasmic eIF4E functions in cap-
dependent translation, the nuclear fraction is involved in se-
lective mRNA transport [18,19]. In this regard, the nuclear
import of eIF4E is mediated by binding to 4E-T (eIF4E-
Transporter) via the importin KL pathway [20]. It is highly
unlikely that 4EHP displays a similar function as it appears to
be essentially a cytoplasmic protein and although it is capable
of binding the 5P mRNA cap structure, it does not bind
eIF4G [14]. Furthermore, it is di⁄cult to imagine how
4EHP could signi¢cantly interfere with the function of
eIF4E as 4EHP is present in cells at only 10% of the level
of eIF4E [14] and HHARI does not interact with eIF4E.
We proposed that HHARI may be an E3 due to structural
similarities to E3s that include Parkin [6] and Dor¢n [11].
Overexpression of HHARI and 4EHP in mammalian cells
yielded increased levels of polyubiquitylated 4EHP. However,
unlike Parkin or Dor¢n, HHARI was not autoubiquitylated
and addition of proteasome inhibitors did not a¡ect the over-
all levels of HHARI-Myc (data herein and [13]).
HHARI-mediated ubiquitylation of 4EHP may alter the
e⁄ciency of its binding to the cap of mRNA. Indeed, we
have preliminary evidence to suggest that this may be the
case. This may promote translation in a similar way to ubiq-
uitylation of transcription factors aids gene transcription [21].
Alternatively, the function of 4EHP binding to capped
mRNA may be to compartmentalise speci¢c mRNA popula-
tions inside cells thereby post-transcriptionally regulating gene
expression [22]. Loss of such a function may be particularly
relevant for mRNA movements down axons and may begin to
explain the phenotypic axonal path¢nding defects observed in
the Drosophila ariadne-1 knock-outs [2,22].
Future investigations will focus on elucidating the poten-
tially complex relationship between eIF4E and 4EHP/
HHARI, protein mono/polyubiquitylation and their potential
roles in the regulation of protein synthesis and/or mRNA
transport.
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